药物警戒数据获取与整合:焦点小组观点
药物安全研究组国际工作组召开焦点小组会议,9名多领域药物警戒专家讨论当前挑战与机遇,强调多模态数据分析和多样数据源可及性的必要性。会议识别了数据标准化、质量差异、技术障碍和伦理问题等关键挑战,提出促进数据透明度、建立安全共享平台和合作联盟等解决方案。
要点
- 多模态数据分析和多样数据源可及性对药物安全监测至关重要。
- 数据标准化、质量差异、技术障碍和伦理问题(尤其社交媒体数据)是主要挑战。
- 知识图谱等新兴工具有助数据整合和信号检测,但需进一步研究。
核心结论
- 需改善数据整合、可及性和方法学严谨性以强化药物警戒实践和全球药品安全监测。
研究设计与样本
- 药物安全研究组国际工作组组织的焦点小组,9名经目的性抽样选择的多部门药物警戒专家参与。
主要发现
- 临床试验数据和真实世界数据各有独特优势和局限性。
- 关键挑战包括数据标准化、质量变异、技术障碍和伦理问题,尤其社交媒体数据。
- 知识图谱等新兴工具有潜力增强数据整合和信号检测,但需进一步研究。
- 数据获取差异涉及监管限制、低资源环境基础设施有限和行业数据获取受限。
临床怎么用
- 提出促进数据透明度、建立安全数据共享平台和形成合作联盟以促进负责任和伦理的数据使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.
引用
- van Hunsel F, Lane S, Cooper D, et al. Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group. Drug Saf. 2026. PMID: 41533330. doi:10.1007/s40264-025-01646-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。